DAWNZERA showed sustained HAE attack rate reduction and long-term safety over two years 71% HAE attack rate reduction maintained after two years on DAWNZERA compared to baseline for patients switching from another long-term prophylactic therapy Treatment effect maintained regardless of dosing
Ionis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual Meeting
calendar_today
November 12, 2026
person
Ionis Pharmaceuticals, Inc. News Releases
domain
ionis-pharmaceuticals